The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
Max S. Topp
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Nicola Goekbuget
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Anthony Selwyn Stein
No relevant relationships to disclose
Ralf C. Bargou
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Hervé Dombret
Research Funding - GRAALL Intergroup
Adele K. Fielding
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Josep M. Ribera
No relevant relationships to disclose
Robin Foà
Consultant or Advisory Role - Amgen
Gerhard Zugmaier
Employment or Leadership Position - Amgen Research Munich GmbH
Stock Ownership - Amgen
Chris Holland
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Tapan Maniar
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Birgit Huber
Employment or Leadership Position - Amgen Research (Munich) GmbH
Stock Ownership - Amgen
Dirk Nagorsen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Hagop M. Kantarjian
Research Funding - Amgen